NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on natural killer cell therapies, with a lead pipeline targeting Alzheimer's disease and other serious conditions. The company completed its business combination with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Acquisition LLC that held its IPO in 2021. Following the de-SPAC merger, NKGen filed a Form 10-Q with the SEC on May 15, 2023, marking one of its first quarterly disclosures as a combined public company. NKGen operates within the cell therapy segment of the broader biopharmaceutical sector. To access complete filing history, sponsor profiles, and deal analytics for NKGN and thousands of other SPAC transactions, sign up for full data on SpacDesk.